{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T13:52:22Z","timestamp":1762782742407},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T00:00:00Z","timestamp":1651622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T00:00:00Z","timestamp":1651622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s00120-022-01841-4","type":"journal-article","created":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T18:04:38Z","timestamp":1651687478000},"page":"1115-1121","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Zystische Erkrankungen in der Urologie"],"prefix":"10.1007","volume":"61","author":[{"given":"H. E.","family":"Kn\u00fcpfer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Keppler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Zienkiewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. J.","family":"Molderings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,4]]},"reference":[{"issue":"16","key":"1841_CR1","doi-asserted-by":"publisher","first-page":"8960","DOI":"10.3390\/ijms22168960","volume":"22","author":"H Seidel","year":"2021","unstructured":"Seidel\u00a0H, Hertfelder\u00a0HJ, Oldenburg\u00a0J et\u00a0al (2021) Effects of primary mast cell disease on hemostasis and erythropoiesis. Int J Mol Sci 22(16):8960","journal-title":"Int J Mol Sci"},{"issue":"30","key":"1841_CR2","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1055\/s-0034-1370055","volume":"139","author":"GJ Molderings","year":"2014","unstructured":"Molderings\u00a0GJ, Homann\u00a0J, Brettner\u00a0S et\u00a0al (2014) Systemische Mastzellaktivierungserkrankung: Ein praxisorientierter Leitfaden zu Diagnostik und Therapie. Dtsch Med Wochenschr 139(30):1523\u20131534","journal-title":"Dtsch Med Wochenschr"},{"issue":"2","key":"1841_CR3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1515\/dx-2020-0005","volume":"8","author":"LB Afrin","year":"2020","unstructured":"Afrin\u00a0LB, Ackerley\u00a0MB, Bluestein\u00a0LS et al (2020) Diagnosis of mast cell activation syndrome: a\u00a0global \u201cconsensus-2\u201d. Diagnosis 8(2):137\u2013152","journal-title":"Diagnosis"},{"issue":"7","key":"1841_CR4","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s00210-016-1247-1","volume":"389","author":"GJ Molderings","year":"2016","unstructured":"Molderings\u00a0GJ, Haenisch\u00a0B, Brettner\u00a0S et\u00a0al (2016) Pharmacological treatment options for mast cell activation disease. Naunyn Schmiedebergs Arch Pharmacol 389(7):671\u2013694","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"7","key":"1841_CR5","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1007\/s00104-019-0935-z","volume":"90","author":"B Sido","year":"2019","unstructured":"Sido\u00a0B, Homann\u00a0J, Hertfelder\u00a0HJ et\u00a0al (2019) Chirurgische Eingriffe bei Patienten mit systemischer Mastzellaktivierungserkrankung : Empfehlungen f\u00fcr das perioperative Management. Chirurg 90(7):548\u2013556","journal-title":"Chirurg"},{"key":"1841_CR6","first-page":"S266","volume":"62","author":"C Gaik","year":"2021","unstructured":"Gaik\u00a0C, Wiesmann\u00a0T (2021) Anaesthesia recommendations for systemic mastocytosis. Anasth Intensivmed 62:S266\u2013S282","journal-title":"Anasth Intensivmed"},{"issue":"6","key":"1841_CR7","first-page":"E849","volume":"20","author":"S Wirz","year":"2017","unstructured":"Wirz\u00a0S, Molderings\u00a0GJ (2017) A practical guide for treatment of pain in patients with systemic mast cell activation disease. Pain Physician 20(6):E849\u2013E861","journal-title":"Pain Physician"},{"issue":"9","key":"1841_CR8","doi-asserted-by":"publisher","first-page":"e76241","DOI":"10.1371\/journal.pone.0076241","volume":"8","author":"GJ Molderings","year":"2013","unstructured":"Molderings\u00a0GJ, Haenisch\u00a0B, Bogdanow\u00a0M et\u00a0al (2013) Familial occurrence of systemic mast cell activation disease. Plos One 8(9):e76241","journal-title":"Plos One"},{"issue":"1","key":"1841_CR9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1159\/000064829","volume":"65","author":"F Ito","year":"2000","unstructured":"Ito\u00a0F, Nakazawa\u00a0H, Ryoji\u00a0O et al (2000) Cytokines accumulated in acquired renal cysts in long-term hemodialysis patients. Urol Int 65(1):21\u201327","journal-title":"Urol Int"},{"key":"1841_CR10","doi-asserted-by":"crossref","unstructured":"Farhadi S, Shahsavari F, Davardan M (2016) The possible role of mast cells in the odontogenic cyst\u2019s pathogenesis: a comparative study between dentigerous cyst and keratocystic odontogenic oumor. Patholog Res Int 2016:8754567","DOI":"10.1155\/2016\/8754567"},{"issue":"5","key":"1841_CR11","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/j.1600-0897.2004.00166.x","volume":"51","author":"H Fujiwara","year":"2004","unstructured":"Fujiwara\u00a0H, Konno\u00a0R, Netsu\u00a0S et\u00a0al (2004) Localization of mast cells in endometrial cysts. Am J Reprod Immunol 51(5):341\u2013344","journal-title":"Am J Reprod Immunol"},{"key":"1841_CR12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.trsl.2016.01.003","volume":"174","author":"LB Afrin","year":"2016","unstructured":"Afrin\u00a0LB (2016) Mast cell activation disease and the modern epidemic of chronic inflammatory disease. Transl Res 174:33\u201359","journal-title":"Transl Res"},{"issue":"4 Suppl","key":"1841_CR13","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.urology.2006.08.1109","volume":"69","author":"GR Sant","year":"2007","unstructured":"Sant\u00a0GR et\u00a0al (2007) The mast cell in interstitial cystitis: role in pathophysiology and pathogenesis. Urology 69(4 Suppl):34\u201340","journal-title":"Urology"},{"issue":"9","key":"1841_CR14","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1136\/jclinpath-2017-204881","volume":"71","author":"ST Malik","year":"2018","unstructured":"Malik\u00a0ST et\u00a0al (2018) Distribution of mast cell subtypes in interstitial cystitis: implications for novel diagnostic and therapeutic strategies? J\u00a0Clin Pathol 71(9):840\u2013844","journal-title":"J Clin Pathol"},{"issue":"1","key":"1841_CR15","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.molimm.2014.03.002","volume":"63","author":"LC Madjene","year":"2015","unstructured":"Madjene\u00a0LC et\u00a0al (2015) Mast cells in renal inflammation and fibrosis: lessons learnt from animal studies. Mol Immunol 63(1):86\u201393","journal-title":"Mol Immunol"},{"issue":"3","key":"1841_CR16","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3109\/07853890.2016.1161231","volume":"48","author":"LB Afrin","year":"2016","unstructured":"Afrin\u00a0LB, Butterfield\u00a0JH, Raithel\u00a0M et\u00a0al (2016) Often seen, rarely recognized: mast cell activation disease\u2014a guide to diagnosis and therapeutic options. Ann Med 48(3):190\u2013201","journal-title":"Ann Med"},{"key":"1841_CR17","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ejphar.2016.02.066","volume":"777","author":"R Reena","year":"2016","unstructured":"Reena\u00a0R et al (2016) Mast cell stabilizers obviate high fat diet-induced renal dysfunction in rats. Eur J Pharmacol 777:96\u2013103","journal-title":"Eur J Pharmacol"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-022-01841-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-022-01841-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-022-01841-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T18:05:15Z","timestamp":1665425115000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-022-01841-4"}},"subtitle":["Handlungsempfehlungen f\u00fcr Patienten mit systemischer Mastzellerkrankung"],"short-title":[],"issued":{"date-parts":[[2022,5,4]]},"references-count":17,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1841"],"URL":"https:\/\/doi.org\/10.1007\/s00120-022-01841-4","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,4]]},"assertion":[{"value":"17 March 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"H.\u00a0E.\u00a0Kn\u00fcpfer, V.\u00a0Keppler und T.\u00a0Zienkiewicz geben an, dass kein Interessenkonflikt besteht. G.\u00a0J.\u00a0Molderings ist Miteigent\u00fcmer und der chief medical officer des Start-up-Unternehmens MC Sciences UG.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die der Patient ggf.\u00a0zu identifizieren w\u00e4re, liegt von ihm eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}